Multiple myeloma, High Refractory Multiple Myeloma
GLPGGalapagos NVCatalyst overview
Research summary
This catalyst tracks a Failed discontinued for GLPG5301 BCMA CAR-T in Multiple myeloma, High Refractory Multiple Myeloma. The expected timing is based on the latest available company guidance and may change.
PAPILIO-1 study. 12/19/23- First patient dosed. 4/21/25- Ongoing participant recruitment. 12/08/25:- Company intends to wind down cell therapy activities; PAPILIO-1 continues during consultation period. 02/24/26:- PAPILIO-1 early terminated; GLPG5301 cell therapy discontinued; patients transition to HESPERIA long-term follow-up.
Verification
Confirm timing and program details against the company announcement or filing.